Leukemia Treatment by Type

People often arrive expecting a stage number. Leukemia does not have one.

The reason is simple. Leukemia begins in the bone marrow and travels in the blood, so it is everywhere from the start. There is no tumour to measure and no lymph node map to follow.

What replaces the stage is a two-part answer. Which type of leukemia is this? And how risky does it look under the microscope and in the gene results?

Those two answers do almost all the work. NCI keeps a separate treatment summary for each of the four common types, because they are genuinely different diseases.

This page explains how each one is organised. It is not advice about your own care.

The oldest split is between acute and chronic.

Acute leukemia is made of immature cells called blasts. They multiply fast and crowd out normal blood production. Treatment usually starts within days of the diagnosis being confirmed.

Chronic leukemia is made of more mature cells. It can build slowly over years. Some people need treatment at once, and some do not need it for a long time.

Both then split by cell line, myeloid or lymphoid. That gives the four names most people meet: AML, ALL, CML and CLL.

AML is diagnosed when blasts reach 20 percent or more of the blood or marrow. Four genetic findings are exceptions to that threshold.

NCI calls chromosome analysis mandatory here. Testing for changes in genes such as NPM1, FLT3, CEBPA and RUNX1 is routine as well. About half of people have a chromosome abnormality, and together these results give the strongest guide to how treatment is likely to go.

Intensive induction chemotherapy is the classic approach. It is seven days of cytarabine given continuously with three days of an anthracycline drug, usually called 7 + 3. NCI reports a complete response rate of about 65 percent. Midostaurin is added when a FLT3 change is present. Gemtuzumab ozogamicin is another drug added in selected cases.

Intensive treatment does not suit everyone. For people who are not candidates for it, NCI lists low-dose cytarabine, decitabine, azacitidine and supportive care alone as reasonable choices. Venetoclax is approved in combination with azacitidine, decitabine or low-dose cytarabine for newly diagnosed AML in adults aged 75 and over, or those whose other health problems rule out intensive induction.

One AML subtype is handled apart from the first hour. Acute promyelocytic leukemia is defined by the PML::RARA fusion, and it carries a serious bleeding risk. NCI treats low- to intermediate-risk cases, meaning a white cell count of 10 x 10^9/L or under, with all-trans retinoic acid and arsenic trioxide and no chemotherapy. Higher-risk cases get retinoic acid with chemotherapy, then arsenic-based consolidation.

Adult ALL treatment is built in phases rather than as one block of chemotherapy.

• Remission induction, to clear the marrow.
• Treatment aimed at the brain and spinal cord.
• Consolidation, sometimes called maintenance, to keep the remission.

The brain and spinal cord phase is not optional. NCI says early treatment there is critical, because the leukemia can otherwise survive in a place most drugs reach poorly. Options include intrathecal methotrexate, high-dose systemic methotrexate, and in some plans cranial radiation.

Sixty to 80 percent of adults reach complete remission after appropriate induction. Regimens usually contain vincristine, prednisone and an anthracycline, with or without asparaginase.

One test changes the plan more than any other. About 20 percent of adult ALL carries the Philadelphia chromosome, which makes the BCR::ABL1 fusion. Adding a drug that blocks it lifts the remission rate above 90 percent. Imatinib is approved for adults with relapsed or refractory Philadelphia-positive ALL, and for children with newly diagnosed disease alongside chemotherapy.

For relapsed or refractory B-cell ALL, NCI lists blinatumomab and inotuzumab ozogamicin, each usually followed by an allogeneic transplant. Blinatumomab's label is broader than that list. It also covers ALL in first or second remission with minimal residual disease at 0.1 percent or above, and Philadelphia-negative B-cell ALL during the consolidation phase.

CAR T-cell therapy is another option NCI's adult summary does not list. Brexucabtagene autoleucel is approved for adults with relapsed or refractory B-cell precursor ALL, and obecabtagene autoleucel is approved in the same setting. If either is raised with you, ask why it fits your case.

CML is the clearest example of a cancer defined by a single genetic event. The Philadelphia chromosome fuses two genes into BCR::ABL1, and the protein it makes drives the disease.

That makes CML unusual in a second way. It is not staged, but it does have phases: chronic, accelerated and blast phase. Most people are diagnosed in chronic phase.

NCI lists five drugs as possible first treatment for chronic-phase disease: asciminib, nilotinib, dasatinib, bosutinib and imatinib. With any of them, NCI reports 10-year event-free and overall survival above 90 percent.

Asciminib works differently from the others. It binds a separate pocket on the protein. It is approved for newly diagnosed chronic-phase disease, for previously treated disease, and for disease carrying the T315I mutation. In a trial of 405 people, the 48-week major molecular response rate was 67.7 percent with asciminib against 49 percent with the comparison drugs. NCI notes the price difference is stark: about 260,000 dollars a year in 2024 against about 500 dollars for imatinib.

Progress here is measured by a blood test, not a scan. The BCR::ABL1 transcript level is tracked over time. A level of 10 percent or less at 3 months predicts the best outcomes. After a year, the usual target is a major molecular response, meaning 0.1 percent or less.

NCI adds a useful caution. Changing treatment purely because of the 3-month number is problematic, because 75 percent of people with a slower response still do well.

CLL is the type where doing nothing is most often the right answer at first.

It has two staging systems of its own, Rai and Binet. Both sort people by whether lymph nodes, spleen and liver are enlarged, and whether the marrow has begun to fail.

NCI cites a meta-analysis of randomised trials showing no survival benefit from treating early-stage disease immediately rather than waiting. This holds even for some people with higher-risk features such as a del(17p) result, though those cases need closer monitoring.

Treatment starts when the disease becomes symptomatic or progressive. The international criteria include worsening anemia or low platelets, a spleen 6 cm or more below the rib margin, lymph nodes 10 cm or larger, a lymphocyte doubling time under 6 months, drenching night sweats for a month, or unintentional weight loss of 10 percent or more in six months.

When treatment is needed, NCI lists BTK inhibitors, meaning acalabrutinib, zanubrutinib or ibrutinib. It also lists venetoclax started with obinutuzumab or rituximab, and combinations of a BTK inhibitor with venetoclax. Chemotherapy-based regimens remain options, but NCI says a chemotherapy-free approach is usually preferred, and is mandatory when del(17p) or a TP53 change is present.

Side effects separate these drugs. NCI reports a 3-year atrial fibrillation risk of 22.7 percent with ibrutinib, and a randomised comparison showing less atrial fibrillation with acalabrutinib than ibrutinib, at 9.4 percent against 16 percent.

SEER reports five-year relative survival for 2016 through 2022 by type:

• Acute myeloid leukemia: 33.4 percent.
• Acute lymphocytic leukemia: 73.2 percent.
• Chronic myeloid leukemia: 71.1 percent.
• Chronic lymphocytic leukemia: 90.2 percent.

Those four numbers are the clearest argument that the word leukemia alone tells you very little. Ask which one applies to you, and what your risk group does to it.

• Call 911 or go to an emergency department if a fever comes with confusion, clammy or sweaty skin, a racing or weak pulse, breathlessness, or extreme pain. CDC lists those as signs of sepsis, which it calls a life-threatening emergency. Low neutrophil counts make it more likely here.
• Call 911 or go to an emergency department if you have a sudden severe headache, new confusion, or weakness on one side. With low platelets, bleeding into the brain is the worry.
• Call 911 or go to an emergency department if bleeding will not stop with pressure, or you vomit blood or pass black tarry stools.
• Ring your leukemia team at once, day or night, if you have a temperature of 100.4°F (38°C) or higher, or shaking chills, even if you feel well otherwise. Feeling well is not reassurance when your neutrophils are near zero, which they are for much of leukemia treatment. CDC treats a fever during chemotherapy as a medical emergency, and units aim to start antibiotics within an hour, so a same-day call back is too slow. If you cannot get hold of them quickly, go to an emergency department and tell reception at once that you are a leukemia patient with a fever, so you are not left in the waiting room.
• Call your care team the same day if you bleed from the gums or nose, see blood in urine or stool, or bruise without injury.
• Call 911 or go to an emergency department if you become breathless at rest, or have chest pain. With a low hemoglobin and a low platelet count, neither is safe to hold overnight.
• Go straight to an emergency department if you develop breathlessness, swelling or fever during retinoic acid or arsenic trioxide treatment. This can be differentiation syndrome, and your counts are low at the same time.
• Call your care team within a day or two if you are more tired or paler than usual, or a mouth ulcer stops you eating or drinking.

What Is Leukemia?, Acute vs Chronic Leukemia, Acute Myeloid Leukemia (AML), and Chronic Lymphocytic Leukemia (CLL).

• https://www.cancer.gov/types/leukemia/hp/adult-aml-treatment-pdq
• https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq
• https://www.cancer.gov/types/leukemia/hp/cml-treatment-pdq
• https://www.cancer.gov/types/leukemia/hp/cll-treatment-pdq
• https://seer.cancer.gov/statfacts/html/amyl.html
• https://seer.cancer.gov/statfacts/html/alyl.html
• https://seer.cancer.gov/statfacts/html/cmyl.html
• https://seer.cancer.gov/statfacts/html/clyl.html
• https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e33001e7-3650-42b1-ae56-cddb5c43aa2b
• https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38b482a8-960b-4591-9857-5031ecb830aa
• https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b118a40d-6b56-cee3-10f6-ded821a97018
• https://www.cdc.gov/sepsis/about/index.html
• https://www.cdc.gov/cancer-preventing-infections/patients/fever.html